When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MGNX - Macrogenics' margetuximab shows survival benefit in late-stage breast cancer study
MacroGenics Inc.
A second pre-planned interim overall survival (OS) analysis of a Phase 3 clinical trial, SOPHIA, evaluating MacroGenics' (NASDAQ:MGNX) margetuximab, an HER2-targeting monoclonal antibody, plus chemo compared to Roche's Herceptin (trastuzumab) plus chemo in patients with HER2-positive metastatic breast cancer showed a median increase of 1.8 months (21.6 months vs. 19.8 months).
More news on: MacroGenics, Inc., Healthcare stocks news,